Neogenomics Inc
Neogenomics Inc focuses on providing genetic oncology research services, including molecular and cytogenetic testing for the diagnosis and treatment of cancer.
Price history of Neogenomics Inc
Price history of Neogenomics Inc
Performance & Momentum
Strategic Analysis
Neogenomics Inc • 2026
NeoGenomics positions itself as a U.S. specialist in oncology diagnostics and molecular genetics, with a business focused on high-value-added laboratory testing. Its model is built on deep clinical expertise and a useful role in the cancer care pathway, where diagnostic precision is a key lever for physicians and partner laboratories.
- Niche positioning in oncology, a segment supported by structural demand for more precise diagnostics
- Recognized expertise in molecular genetics and specialized testing, difficult to replicate in the short term
- Exposure to a defensive healthcare market, with recurring diagnostic needs
- A very poor stock-market performance over several years, reflecting execution or profitability that has been insufficiently convincing
- Dependence on the reimbursement environment and testing volumes, which can weigh on commercial visibility
Momentum is moderately positive in the short term, with a recent recovery that contrasts with an underlying trend that remains fragile over several years. For investors, this points to a speculative rebound story rather than a growth stock that has already re-established a durable trajectory. In the absence of any recent major news, the stock remains one that is sensitive to any operational or commercial improvement, but still exposed to volatility.
Similar stocks to Neogenomics Inc
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
